UCB (OTCMKTS:UCBJF) Shares Gap Down – Should You Sell?

UCB SA (OTCMKTS:UCBJF)’s share price gapped down prior to trading on Friday . The stock had previously closed at $340.0375, but opened at $320.89. UCB shares last traded at $338.24, with a volume of 4 shares.

Analyst Upgrades and Downgrades

UCBJF has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a report on Monday, December 8th. Stephens reissued an “overweight” rating on shares of UCB in a report on Thursday, January 15th. Barclays restated an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research report on Monday, February 16th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy”.

UCB Stock Performance

The business’s 50-day simple moving average is $305.24 and its 200 day simple moving average is $278.11. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.